CVS Health shares rise amid Medicare payment increase
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 20 hours ago
0mins
Should l Buy CVS?
Source: seekingalpha
CVS Health Corp's stock has increased by 7.33% in pre-market trading, reaching a 5-day high.
This surge follows the Trump administration's announcement of a 2.48% increase in average Medicare Advantage payments for 2027, which is expected to enhance insurers' profitability. The positive market reaction saw CVS Health's shares jump over 9%, reflecting strong investor optimism regarding the policy change.
The increase in Medicare payments is likely to improve CVS Health's financial outlook, as it serves a significant number of Medicare Advantage beneficiaries, thereby potentially boosting its revenue and market position.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CVS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CVS
Wall Street analysts forecast CVS stock price to rise
17 Analyst Rating
16 Buy
1 Hold
0 Sell
Strong Buy
Current: 78.790
Low
91.00
Averages
96.71
High
105.00
Current: 78.790
Low
91.00
Averages
96.71
High
105.00
About CVS
CVS Health Corporation is a health solutions company. The Company's segments include Health Care Benefits, Health Services, Pharmacy & Consumer Wellness and Corporate/Other. The Health Care Benefits segment offers a broad range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, PDPs and Medicaid health care management services. The Health Services segment provides a full range of pharmacy benefit management (PBM) solutions through its CVS Caremark operations and delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its CVS Pharmacy retail locations and, through its infusion operations, provides ancillary pharmacy services including pharmacy patient care programs, and vaccination administration, and sells a wide assortment of health and wellness products and general merchandise.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Safe Investment Choices Amid Economic Recession
- CVS Health's Resilience: With a vast network of pharmacies and a strong insurance business, CVS Health is well-positioned to perform relatively well during recessions, boasting a market cap of $100 billion and a dividend yield of 3.37%, providing investors with stable cash flow.
- Long-Term Growth Potential: As the aging population increases demand for medical services, CVS Health is expected to benefit from long-term growth, currently trading at a price-to-earnings ratio of 10.3, significantly lower than the healthcare sector average of 16.8, indicating its attractiveness.
- Valuation Advantage for Bristol Myers: Bristol Myers Squibb's shares are currently trading at a low price-to-earnings ratio of 9.5, suggesting undervaluation; despite facing patent cliffs, the launch of new products is expected to drive recovery and growth.
- Stable Dividend Policy: Bristol Myers has maintained its dividend without cuts for the past 20 years, with a dividend yield of 4.20%, demonstrating financial resilience during downturns, making it appealing to income-seeking investors.
See More
CVS Health and Bristol Myers Squibb Positioned for Economic Resilience
- Recession Resilience: CVS Health has maintained or increased its dividends over the past 20 years, demonstrating stability during economic downturns, particularly after experiencing multiple shocks like the 2008 financial crisis and the pandemic, indicating its business model can perform well across economic cycles.
- Dividend Appeal: CVS's dividend program provides investors with stable income, helping to mitigate losses during market downturns, with its current stock trading at a forward P/E of 10.3, which is attractive compared to the healthcare sector average of 16.8.
- New Product Drivers: Bristol Myers Squibb's shares are currently trading at a forward P/E of 9.5, and despite facing patent expirations, its newly launched subcutaneous version of the oncology drug Opdivo is expected to support future revenue growth, showcasing its strong portfolio across multiple therapeutic areas.
- Stable Dividend Policy: Bristol Myers Squibb has not suspended or reduced its dividend in the past two decades, further proving its resilience during economic downturns, making it a top choice for income-seeking investors preparing their portfolios for a recession.
See More
CVS Stock Faces Regulatory Headwinds
- Regulatory Pressure Intensifies: CVS stock experienced a decline in afternoon trading on April 7, 2026, reflecting market concerns over the regulatory challenges the company faces, which could impact its future profitability and market performance.
- Market Reaction Evident: Although CVS saw a slight increase of 0.06% in stock price on the same day, the overall trend indicates that investors are cautious about the company's ability to adapt to the regulatory environment, potentially leading to a decrease in investor confidence.
- Uncertain Future Outlook: As regulatory policies continue to evolve, CVS must implement effective strategies to address these challenges in order to maintain its market position and ensure sustained growth, particularly in the highly competitive healthcare sector.
- Investor Focus: The intensifying regulatory issues have made CVS a focal point for investors, and analysts may reassess its stock ratings and price targets, which could affect the company's future financing capabilities and market valuation.
See More
Health Insurance Stocks Surge Following Medicare Payment Increase
- Payment Increase Impact: The Trump administration's announcement of a 2.48% increase in Medicare Advantage payments for 2027, translating to over $13 billion, led to a significant surge in major insurers' stock prices, with UnitedHealth Group (UNH) rising 9.4%, reflecting market optimism about the healthcare sector's outlook.
- Strong Market Reaction: This payment increase starkly contrasts with the proposed 0.09% hike in January, which had previously caused a sharp decline in insurance stocks, indicating the market's sensitivity to policy changes and their substantial impact on the industry.
- Divergent Analyst Views: While the payment increase is seen as a positive signal, analysts remain cautious about its ability to sustain a long-term rally, noting that medical cost inflation remains between 8-10%, which may lead to ongoing margin pressures.
- Future Outlook: Analysts expect insurers to submit more competitive bids by the June deadline, leveraging this revenue windfall to restore supplemental benefits and recapture lost market share, showcasing the industry's potential recovery capability under supportive policies.
See More
GLP-1 Drugs Drive Growth in U.S. Apparel Spending
- Surge in Apparel Demand: Approximately 80% of GLP-1 users anticipate needing new clothing due to size changes, with a Circana survey revealing that 55% of active users have already purchased new items, indicating a fresh wave of consumer spending in the apparel market.
- Significant Market Potential: Bernstein estimates that GLP-1 users could purchase between 150 million and 700 million apparel items due to weight loss, translating to an additional $13 billion in annual spending in the U.S. apparel sector, highlighting robust market demand.
- Brands Adapting to Change: Retailers like Stitch Fix have launched targeted marketing campaigns for weight loss users, with client mentions of weight loss requests tripling over the past two years, demonstrating brands' proactive adaptation to this emerging trend.
- Shift in Consumer Behavior: An increasing number of consumers are opting for more affordable clothing during their weight loss journey, with Destination XL's CEO noting that about 25% of their customers are using GLP-1 drugs, leading to a preference for cost-effective options.
See More
Aetna Releases Inaugural Provider Survey Findings
- Trust Improvement: The inaugural Aetna Provider Survey reveals that over 50% of respondents are optimistic about the healthcare system becoming less burdensome in the next five years, indicating an increase in industry trust and areas for improvement.
- Prior Authorization Simplification: 65% of respondents agree that prior authorization is necessary in the healthcare system, with Aetna currently approving over 95% of prior authorization requests within 24 hours, targeting 80% of electronic requests to be executed in real-time by the end of 2026.
- Technology-Driven Operational Excellence: The survey indicates that 52% of providers believe AI will simplify and accelerate administrative processes, with Aetna automating over one million incoming calls related to prior authorization, enhancing operational efficiency.
- Optimistic Future Outlook: The survey shows that 87% of respondents believe technological advancements will lead to better health outcomes in the next five years, and 76% prioritize technology as a top investment area over the next three years, reflecting the industry's focus on tech investments.
See More
Safe Investment Choices Amid Economic Recession
- CVS Health's Resilience: With a vast network of pharmacies and a strong insurance business, CVS Health is well-positioned to perform relatively well during recessions, boasting a market cap of $100 billion and a dividend yield of 3.37%, providing investors with stable cash flow.
- Long-Term Growth Potential: As the aging population increases demand for medical services, CVS Health is expected to benefit from long-term growth, currently trading at a price-to-earnings ratio of 10.3, significantly lower than the healthcare sector average of 16.8, indicating its attractiveness.
- Valuation Advantage for Bristol Myers: Bristol Myers Squibb's shares are currently trading at a low price-to-earnings ratio of 9.5, suggesting undervaluation; despite facing patent cliffs, the launch of new products is expected to drive recovery and growth.
- Stable Dividend Policy: Bristol Myers has maintained its dividend without cuts for the past 20 years, with a dividend yield of 4.20%, demonstrating financial resilience during downturns, making it appealing to income-seeking investors.
See More
CVS Health and Bristol Myers Squibb Positioned for Economic Resilience
- Recession Resilience: CVS Health has maintained or increased its dividends over the past 20 years, demonstrating stability during economic downturns, particularly after experiencing multiple shocks like the 2008 financial crisis and the pandemic, indicating its business model can perform well across economic cycles.
- Dividend Appeal: CVS's dividend program provides investors with stable income, helping to mitigate losses during market downturns, with its current stock trading at a forward P/E of 10.3, which is attractive compared to the healthcare sector average of 16.8.
- New Product Drivers: Bristol Myers Squibb's shares are currently trading at a forward P/E of 9.5, and despite facing patent expirations, its newly launched subcutaneous version of the oncology drug Opdivo is expected to support future revenue growth, showcasing its strong portfolio across multiple therapeutic areas.
- Stable Dividend Policy: Bristol Myers Squibb has not suspended or reduced its dividend in the past two decades, further proving its resilience during economic downturns, making it a top choice for income-seeking investors preparing their portfolios for a recession.
See More
CVS Stock Faces Regulatory Headwinds
- Regulatory Pressure Intensifies: CVS stock experienced a decline in afternoon trading on April 7, 2026, reflecting market concerns over the regulatory challenges the company faces, which could impact its future profitability and market performance.
- Market Reaction Evident: Although CVS saw a slight increase of 0.06% in stock price on the same day, the overall trend indicates that investors are cautious about the company's ability to adapt to the regulatory environment, potentially leading to a decrease in investor confidence.
- Uncertain Future Outlook: As regulatory policies continue to evolve, CVS must implement effective strategies to address these challenges in order to maintain its market position and ensure sustained growth, particularly in the highly competitive healthcare sector.
- Investor Focus: The intensifying regulatory issues have made CVS a focal point for investors, and analysts may reassess its stock ratings and price targets, which could affect the company's future financing capabilities and market valuation.
See More
Health Insurance Stocks Surge Following Medicare Payment Increase
- Payment Increase Impact: The Trump administration's announcement of a 2.48% increase in Medicare Advantage payments for 2027, translating to over $13 billion, led to a significant surge in major insurers' stock prices, with UnitedHealth Group (UNH) rising 9.4%, reflecting market optimism about the healthcare sector's outlook.
- Strong Market Reaction: This payment increase starkly contrasts with the proposed 0.09% hike in January, which had previously caused a sharp decline in insurance stocks, indicating the market's sensitivity to policy changes and their substantial impact on the industry.
- Divergent Analyst Views: While the payment increase is seen as a positive signal, analysts remain cautious about its ability to sustain a long-term rally, noting that medical cost inflation remains between 8-10%, which may lead to ongoing margin pressures.
- Future Outlook: Analysts expect insurers to submit more competitive bids by the June deadline, leveraging this revenue windfall to restore supplemental benefits and recapture lost market share, showcasing the industry's potential recovery capability under supportive policies.
See More
GLP-1 Drugs Drive Growth in U.S. Apparel Spending
- Surge in Apparel Demand: Approximately 80% of GLP-1 users anticipate needing new clothing due to size changes, with a Circana survey revealing that 55% of active users have already purchased new items, indicating a fresh wave of consumer spending in the apparel market.
- Significant Market Potential: Bernstein estimates that GLP-1 users could purchase between 150 million and 700 million apparel items due to weight loss, translating to an additional $13 billion in annual spending in the U.S. apparel sector, highlighting robust market demand.
- Brands Adapting to Change: Retailers like Stitch Fix have launched targeted marketing campaigns for weight loss users, with client mentions of weight loss requests tripling over the past two years, demonstrating brands' proactive adaptation to this emerging trend.
- Shift in Consumer Behavior: An increasing number of consumers are opting for more affordable clothing during their weight loss journey, with Destination XL's CEO noting that about 25% of their customers are using GLP-1 drugs, leading to a preference for cost-effective options.
See More
Aetna Releases Inaugural Provider Survey Findings
- Trust Improvement: The inaugural Aetna Provider Survey reveals that over 50% of respondents are optimistic about the healthcare system becoming less burdensome in the next five years, indicating an increase in industry trust and areas for improvement.
- Prior Authorization Simplification: 65% of respondents agree that prior authorization is necessary in the healthcare system, with Aetna currently approving over 95% of prior authorization requests within 24 hours, targeting 80% of electronic requests to be executed in real-time by the end of 2026.
- Technology-Driven Operational Excellence: The survey indicates that 52% of providers believe AI will simplify and accelerate administrative processes, with Aetna automating over one million incoming calls related to prior authorization, enhancing operational efficiency.
- Optimistic Future Outlook: The survey shows that 87% of respondents believe technological advancements will lead to better health outcomes in the next five years, and 76% prioritize technology as a top investment area over the next three years, reflecting the industry's focus on tech investments.
See More
